Scientists have discovered two new antigens in a species of malaria-causing parasite P. falciparum that elicit antibodies that appear in humans and are linked with lower malaria transmission in mice. The findings that could inform the development of a malaria vaccine that disrupts the parasite’s life cycle and prevents the transmission of malaria.
McMaster University scientists say they have discovered a previously unknown mechanism which acts like a spider web, trapping and killing pathogens such as influenza or SARS-CoV-2. The finding has implications for vaccine design and delivery, including aerosol and nasal spray technologies that could help the body head off infections before they can take hold.
The rapid increase in demand for mRNA therapeutics has revealed the inherent challenge of the platform—that the production of mRNA is facing a series of bottlenecks. In this sponsored GEN webinar, we will hear how scientists at Sartorius have been working on streamlining these challenges long before the pandemic even started.
The company’s platform is designed to activate immune responses against cancer and infectious diseases.
The organization will provide vaccines in developing countries. Schering-Plough will provide World Health Organization (WHO) with access to pandemic influenza vaccine manufacturing technology in developing...
A clinical trial conducted at the University of North Carolina Lineberger Comprehensive Cancer Center and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center found that high-dose cytarabine followed by subsequent immunotherapy treatment with pembrolizumab benefited patients with resistant or relapsed acute myeloid leukemia (AML). Study results compare favorably to remission rates seen with high-dose cytarabine and other chemotherapy regimens in resistant or relapsed AML.
William A. Haseltine, PhD, is known for his groundbreaking work on HIV/AIDS and the human genome. He is president of the Haseltine Foundation and founder, chairman, and president of ACCESS International. In this commentary Dr. Haseltine talks about the commercialization of bioresearch.
90,000 sq. ft. facility is to be built for the manufacture of 10 million doses/month.
A new study presents data from the first in-human trial to test the efficacy of focused ultrasound to deliver drugs through the blood-brain barrier. The data, from four out of 10 participants, show that the technique enhanced delivery of antibody therapy to breast cancer that has metastasized to the brain. The safe and effective technique paves the way for the use of this method for other neurological conditions.
Researchers have identified and tested an antibody that limits the severity of infections from a variety of coronaviruses, including those that cause COVID-19 as well as the original SARS. The therapeutic activity suggests that this could be a treatment deployed in the current pandemic and potentially stockpiled to prevent the spread of a future outbreak or epidemic with a SARS-related virus.